[Initial experiences with a new cytostatic agent (IMET 3106=1-methyl-2-(p-(bis-(beta-chlorethyl)-amino)-phenyliminomethyl)-quinolinium chloride)].
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy; D005260:Female; D006801:Humans; D007097:Imines / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010166:Palliative Care; D011806:Quinolinium Compounds / Q000627:therapeutic use; D012075:Remission, Spontaneous
D007097:Imines; D009588:Nitrogen Mustard Compounds; D011806:Quinolinium Compounds
Erste klinische Erfahrungen mit einem neuen Zytostatikum (IMET 3106=1-Methyl-2-(p-(bis-(beta-chloräthyl)-amino)-phenyliminomethyl)-chinolinium-chlorid.